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Spondyloarthritis
AbstrAct
Objective acute anterior uveitis (aaU) is the most 
common extra-articular manifestation of axial 
spondyloarthritis (axSpa). in this study, patients presenting 
with aaU were evaluated clinically and with Mri in order to 
estimate the prevalence of axSpa.
Methods consecutive patients presenting to a university 
teaching hospital between February 2014 and March 2015 
with aaU were invited to participate. those with a history 
of chronic back pain (cBP) beginning <45 years were 
evaluated clinically and with Mri of thoracolumbar spine 
and sacroiliac joints.
Results Of 366 patients with aaU, 57 had a pre-existing 
diagnosis of axSpa; 77 others fulfilled the study eligibility 
criteria and 73 (95%) completed the study. Seventeen 
patients (23.3%) were diagnosed with axSpa by an 
experienced rheumatologist; of these, eight were human 
leucocyte antigen-B27 negative. including those with a 
previous diagnosis, this equates to a minimum axSpa 
prevalence of 20.2%; one-quarter of patients were 
previously undiagnosed.
Conclusion this is the first study to actively search for the 
presence of axSpa in unselected patients presenting with 
aaU utilising Mri as an essential part of the assessment. 
there is a significant burden of undiagnosed axSpa in 
patients with aaU, but there does not appear to be a 
simple mechanism for screening. We recommend that 
ophthalmologists refer all patients with aaU with cBP, 
onset <45 years, to rheumatology for further evaluation.
InTROduCTIOn
Axial spondyloarthritis (axSpA) is a chronic 
inflammatory disease which primarily affects 
the axial skeleton. The prevalence is approx-
imately 0.7% in the general population,1 
and there is a strong genetic association with 
human leucocyte antigen (HLA)-B27.2 Symp-
toms usually begin in the second or third 
decade3 and can have a major impact on 
health and quality of life.4 The spectrum of 
axSpA as defined by the Assessment of Spon-
dyloarthritis International Society (ASAS) 
includes non-radiographic axSpA and anky-
losing spondylitis (AS).2 
Acute anterior uveitis (AAU) is the most 
common extra-articular manifestation of 
axSpA5 6; its prevalence increasing with 
disease duration.7 Diagnostic delay is reported 
frequently in axSpA3 8 9 and is associated with 
worse outcomes.10 Given that spinal symp-
toms usually precede the first episode of AAU, 
targeted screening of patients presenting 
with AAU may enable an earlier diagnosis of 
axSpA.
In this study, patients with AAU were evalu-
ated clinically by an experienced rheumatolo-
gist and underwent MRI in order to estimate 
the prevalence of axSpA and determine the 
hidden burden of disease.
MeThOds
Patients
Consecutive adult patients presenting to the 
ophthalmology department of a teaching 
hospital with a verified diagnosis of non-trau-
matic, non-infective AAU between February 
2014 and March 2015 were invited by letter 
to participate. A further letter was sent to 
Key messages
What is already known about this subject? 
 ► acute anterior uveitis (aaU) is known to be the 
most common extra-articular manifestation of axial 
spondyloarthritis (axSpa).
What does this study add? 
 ► in this study, the minimum prevalence of axSpa in 
aaU was 20.2%, with nearly one-quarter of patients 
previously undiagnosed despite many years of back 
pain.
how might this impact on clinical practice? 
 ► there is no easy referral strategy; previously 
published pathways would have missed a 
significant amount of new diagnoses in our cohort. 
 ► We recommend that ophthalmologists refer all 
patients with aaU with chronic back pain, onset 
<45 years, to rheumatology for further evaluation 
regardless of human leucocyte antigen-B27 status, 
gender or number of episodes of aaU.
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non-responders. Patients with a self-reported history of 
chronic back pain (CBP) beginning before the age of 45 
years were included. Those with a pre-existing diagnosis 
of axSpA, sarcoidosis or Behçet’s disease, or in whom 
MRI was contraindicated, were not investigated further. 
The hospital notes of patients with a reported diagnosis 
of axSpA, including AS, were interrogated to confirm 
that the diagnosis had already been made by an experi-
enced rheumatologist.
Clinical assessment
Patients who agreed to participate were reviewed by 
an experienced rheumatologist; clinical assessment 
included history, physical examination, patient-re-
ported outcome measures and laboratory investiga-
tions.
MRI
MR examinations were performed using a standard 
protocol for imaging individuals with suspected axSpA, 
including spectral fat saturation images of the thora-
columbar spine and sacroiliac joints (SIJ). Images were 
reported by experienced musculoskeletal radiologists 
blinded to the clinical data and verified by an experi-
enced rheumatologist (MS).
diagnosis
The diagnosis of axSpA was made by an experienced 
rheumatologist following review of the clinical history, 
examination, laboratory and MRI findings.
statistics
Results are reported as means (compared using the 
two-tailed Student’s t-test) or percentages (compared 
using the Χ2 test or Fisher’s exact probability test).
ResulTs
Recruitment through the study is shown in figure 1. Of 
366 patients who presented with non-traumatic, non-in-
fective AAU, 241 (66%) responded to the invitation; 57 
subjects were already diagnosed with axSpA (verified 
from clinical notes); 77 others were eligible for the study 
and 73 (95%) completed the study, including under-
going MRI. Responders were older than non-responders 
(P<0.0001) and were more likely to be female (P=0.006).
Seventeen subjects (23.3%) were diagnosed with 
axSpA by an experienced rheumatologist. Of these, 13 
fulfilled the ASAS classification criteria2 (12 imaging and 
one clinical). Of the four remaining patients, three had 
widespread entheseal oedema on spinal MRI, consistent 
with the ASAS definition of a positive spinal MRI,11 and 
although the fourth patient had an equivocal SIJ MRI, 
the clinical phenotype was typical of axSpA in view of 
prominent inflammatory-type back pain (IBP) and 
Crohn’s disease which was already being treated with 
infliximab. Twelve additional patients fulfilled the clin-
ical arm of the ASAS classification criteria but were not 
considered to have axSpA when assessed by an experi-
enced rheumatologist.
Table 1 summarises the MRI findings in the patients 
newly diagnosed with axSpA.
Figure 1 Consort diagram. AxSpA, axial spondyloarthritis. 
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Table 1 MRI findings in patients diagnosed with axial spondyloarthritis
Patient number Active changes Chronic changes
Meets ASAS definition of 
positive SIJ MRI ?
1
43, male
B27 positive
Single area of SIJ BMO Fatty changes around SIJs Yes
2
58, male
B27 negative
Multiple inflammatory vertebral 
corner lesions, but no SIJ BMO
No No
3
67, male
B27 negative
Bilateral SIJ BMO Partial SIJ ankylosis Yes
4
40, female
B27 negative
Bilateral SIJ BMO SIJ erosions Yes
5
60, female
B27 positive
Bilateral SIJ BMO SIJ erosions Yes
6
69, male
B27 negative
Right SIJ BMO and BMO of 
multiple thoracic costovertebral 
joints
Fused left SIJ, sclerosis 
of multiple thoracic 
costovertebral joints
Yes
7
31, female
B27 negative
Single non-specific area of BMO 
around left SIJ
None No
8
34, female
B27 negative
Left SIJ BMO Erosion of right SIJ, multiple 
vertebral fatty corner lesions in 
thoracic spine
Yes
9
58, male
B27 positive
Left SIJ BMO Ankylosis right SIJ, erosions 
left SIJ
Yes
10
57, male
B27 negative
Non-specific SIJ BMO; multiple 
inflammatory vertebral corner 
lesions
None No
11
50, female
B27 positive
None Multiple vertebral fatty corner 
lesions
No
12
31, male
B27 negative
Bilateral SIJ BMO None Yes
13
42, male
B27 positive
Left SIJ BMO Vertebral fatty corner lesions 
T7–T12
Yes
14
49, female
B27 positive
Bilateral SIJ BMO and two 
inflammatory vertebral corner 
lesions in thoracolumbar spine
Fatty change both SIJs Yes
15
58, female
B27 positive
Bilateral SIJ BMO Bilateral SIJ erosions Yes
16
39, female
B27 positive
Bilateral SIJ BMO Partial fusion both SIJ 
inferiorly
Yes
17
45, female
B27 positive
Multiple inflammatory vertebral 
corner lesions
Sclerotic right SIJ No
ASAS, Assessment of Spondyloarthritis International Society; BMO, bone marrow oedema; SIJ, sacroiliac joint
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Findings in the 56 patients not diagnosed with axSpA 
were: degenerative/mechanical spinal changes (including 
prolapsed intervertebral discs, dehydrated intervertebral 
discs, lumbar spondylosis, spondylolisthesis, scoliosis and 
facet joint osteoarthritis) in 40 patients; of these, five had 
a single ‘inflammatory’ corner lesion at one level, asso-
ciated with mechanical disc disease; two had Scheuer-
mann’s disease; six had osteoarthritis of the SIJs with a 
small area of secondary bone marrow oedema (BMO) 
in two of these patients; osteitis condensans ilii in one 
patient and fibrous dysplasia in the iliac bone in one 
patient. Some patients had more than one of these find-
ings and there were 10 entirely normal scans.
Including those with a previous diagnosis verified by an 
experienced rheumatologist (57 patients), this equates 
to an estimated minimum axSpA prevalence of 20.2% 
(95% CI 16.1 to 24.3). Of these, 22.9% were previously 
undiagnosed.
Table 2 outlines the demographics and clinical charac-
teristics of study participants.
Those diagnosed with axSpA were more likely to be 
have a raised C-reactive protein (P=0.014), have a prior 
diagnosis of inflammatory bowel disease (P=0.009) and 
have a higher Bath Ankylosing Spondylitis Metrology 
Index (P=0.001). A larger proportion of patients diag-
nosed with axSpA were HLA-B27 positive, but this did 
not reach statistical significance. IBP did not predict a 
physician diagnosis of axSpA.
Five patients (29.4%) were diagnosed following a single 
episode of uveitis. Two of these patients were HLA-B27 
negative.
dIsCussIOn
This is the first study to actively search for the presence 
of axSpA in unselected patients presenting with AAU 
Table 2 Clinical characteristics of subjects
AxSpA (physician diagnosis) Not axSpA
Test of significance 
P value
Number of subjects 17 (23.3%) 56 (76.7%) N/A
Mean age in years (SD) 48.9 (12.0) 47.6 (11.8) 0.699
Female 9 (52.9%) 37 (66.1%) 0.394
Human leucocyte antigen-B27 positive 9 (52.9%) 19 (25.0%) 0.167
Smoking status
current/ex/never (%)
35.3/17.6/47.1 12.7/40.0/45.5 0.093
Mean number of episodes of uveitis— patient 
reported (SD)
7.4 (13.9) 3.9 (5.2) 0.124
Psoriasis 1 (5.9%) 6 (10.7%) 1.000
Inflammatory bowel disease 4 (23.5%) 1 (1.8%) 0.009*
Reported history of peripheral joint swelling 3 (17.6%) 10 (17.9%) 1.000
Family history of axSpA 1 (5.9%) 3 (5.4%) 1.000
Mean duration of back pain in years (SD) 23.6 (13.2) 17.8 (10.3) 0.061
Mean duration of back pain at first episode of uveitis 
in years (SD)
16.2 (12.5) 14.5 (10.7) 0.511
Maastricht Ankylosing Spondylitis Enthesitis Score 
(SD)
0.47 (0.87) 0.59 (1.37) 0.738
Joint count (SD) 0.88 (2.55) 0.98 (4.84) 0.935
Bath Ankylosing Spondylitis Metrology Index (SD) 1.64 (1.32) 0.69 (0.95) 0.001*
Bath Ankylosing Spondylitis Functional Index (SD) 2.88 (2.21) 2.52 (2.27) 0.564
Bath Ankylosing Spondylitis Global Score (SD) 4.66 (1.41) 4.52 (2.01) 0.782
Bath Ankylosing Spondylitis Disease Activity Index 
(SD)
3.36 (1.66) 3.42 (1.92) 0.904
Spinal pain Visual Analogue Score (SD) 4.47 (2.07) 4.42 (2.42) 0.936
Elevated
C-reactive protein 
5 (29.4%) 3 (5.4%) 0.014*
Meets Assessment of Spondyloarthritis International 
Society inflammatory back pain criteria
6 (35.3%) 23 (41.1%) 0.781
Test of significance is two-tailed t-test for continuous variables and χ2 test or Fisher’s exact probability test for categorical variables. Unless 
otherwise indicated values are n (%).
*Statistical significance.
AxSpA, axial spondyloarthritis; N/A, not applicable.
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utilising MRI as an essential part of the assessment. 
Including patients with a prior diagnosis, the minimum 
prevalence of axSpA is 20.2%, with nearly one-quarter 
of patients previously undiagnosed despite years of back 
pain. This represents a significant hidden burden of 
disease.
Two other studies have recently investigated axSpA 
prevalence in patients with AAU.12 13 However, as known 
cases were excluded, neither study could report the 
overall prevalence of axSpA in the group. Juanola et al12 
also excluded HLA-B27 negative patients with a single 
episode of AAU, but in our cohort, 12% of patients 
newly diagnosed with axSpA met those exclusion criteria. 
Haroon et al13 reported that 40% of patients presenting 
with AAU had undiagnosed SpA, although it is unclear 
how many of these patients underwent MRI.
Although this is a relatively small single-centre study, 
the sample size was sufficient to calculate the prevalence 
with a reasonable degree of precision. The main risk of 
bias is in the self-selection of responders to the initial 
invitation; responders were significantly more likely to 
be older and female. We have made the assumption that 
non-responders did not have back pain, or by extension 
axSpA, and have presented our results as minimum esti-
mated prevalence. However, we accept this could have 
led to an underestimate of the overall prevalence. We 
also based our calculations on diagnoses made by an 
experienced rheumatologist; it is not always clear how 
other studies arrived at their figures and, for example, 
had we included all patients who met the ASAS classifi-
cation criteria within the ‘positive diagnoses’ (which we 
are very clear is not how classification criteria should be 
used), 40% patients assessed would have been assigned a 
‘diagnosis’ of axSpA.
Establishing a diagnosis of axSpA is difficult; conse-
quently, there is often a considerable delay to diag-
nosis and a potential to ‘over diagnose’ based on subtle 
or non-specific MRI changes.14 The gold standard is 
‘physician-verified diagnosis’, which is based on clin-
ical assessment including interpretation of laboratory 
tests and imaging. Classification criteria should only be 
applied following diagnosis and have been developed to 
ensure homogeneity in groups of patients for research 
purposes,15 although the positive predictive validity of the 
ASAS axSpA classification criteria to forecast an expert’s 
diagnosis of ‘SpA’ after more than 4 years is good.16 The 
imaging arm of the ASAS axSpA classification criteria 
requires the presence of sacroiliitis on MRI or X-ray and 
the ASAS/Outcome Measures in Rheumatology defini-
tion of a positive spinal MRI11 is not currently included in 
the formal ASAS classification system and so potentially 
patients with spinal inflammation in the absence of sacro-
iliac inflammation could be overlooked. This observation 
has been well described especially in patients with long-
standing disease.17 One of the potential limitations of an 
MRI-based study is the potential to over or misinterpret 
MRI findings. Three of our B27-negative patients diag-
nosed as axSpA did not fulfil the ASAS definition of a 
positive SIJ MRI; however, we consider any potential ‘over 
diagnosis’ unlikely by virtue of them having a typical 
axSpA clinical phenotype verified an experienced rheu-
matologist including IBP onset <45 years, recurrent AAU 
and extensive spinal inflammatory lesions seen on MRI. 
Conversely, there were many more patients (12) who 
fulfilled the ASAS classification criteria who we consid-
ered not to have the disease.
Other potential limitations include the fact that only 
a single MRI was undertaken, so potentially fluctuating 
BMO could have been missed18 19 and that plain radio-
graphs were not undertaken. This was due to the fact that 
ethics approval was not forthcoming as it was considered 
that this would expose too many patients to unneces-
sary radiation, and MRI was being undertaken as a more 
comprehensive imaging modality. As a result of a lack of 
plain radiographs, we cannot state how many patients 
met the modified New York Criteria for AS. Many patients 
had chronic changes on MRI which may reflect the long 
average delay to diagnosis of over 20 years. Had these 
patients been screened for axSpA following their first 
episode of AAU, the diagnostic delay could have been 
reduced by 7 years on average. Given the high prevalence 
of axSpA among patients with AAU, targeted screening 
may offer a unique opportunity to identify undiagnosed 
axSpA especially as AAU may prompt the first interaction 
with secondary care.20
In clinical practice, HLA-B27 positivity is often the 
trigger for a rheumatology referral in patients with AAU. 
Indeed, the Dublin Uveitis Evaluation Tool (DUET) 
algorithm proposed by Haroon et al prompts referral if 
a patient is HLA-B27 positive (or has co-existing psori-
asis or peripheral arthritis), with high reported sensitivity 
and specificity of 96% and 97%, respectively.13 This may 
reflect the status of HLA-B27 as the anchor criterion 
for the clinical arm of the ASAS criteria. In our cohort, 
the sensitivity and specificity of the DUET algorithm 
were 52.9% (95% CI 27.8 to 77.0) and 67.9% (95% CI 
54.0 to 79.7), respectively. Nearly half of new diagnoses 
were HLA-B27 negative (none of whom had psoriasis or 
a recent history of joint pains requiring a GP visit). By 
applying the DUET algorithm, these HLA-B27 negative 
patients would have been overlooked. Similarly, the pres-
ence of IBP did not predict the diagnosis of axSpA or 
a positive MRI. Had we relied on IBP rather than CBP 
before age 45 as a referral strategy, nearly two-thirds of 
new diagnoses would have been overlooked.
In summary, there is a high prevalence of undiagnosed 
axSpA in patients presenting to secondary care with AAU. 
There does not appear to be a simple mechanism for 
screening these patients, so given the significant burden 
of ‘hidden’ axSpA, we recommend that ophthalmologists 
refer all patients with AAU with CBP, onset <45 years, 
to rheumatology for further evaluation regardless of 
HLA-B27 status, gender or number of episodes of AAU. 
Close collaboration between rheumatology and ophthal-
mology is necessary in order to facilitate this targeted 
approach to patient care.
copyright.
 o
n
 August 24, 2020 at University of East Anglia. Protected by
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000553 on 24 February 2018. Downloaded from
 
6 Sykes MP, et al. RMD Open 2018;4:e000553. doi:10.1136/rmdopen-2017-000553
RMD Open
Contributors all authors were involved in the data collection and had input into 
the final report.
Funding this study was funded by abbVie ltd.
Competing interests none declared.
Patient consent Obtained.
ethics approval ethical approval was provided by nreS committee east of england 
– norfolk (reference number 13/ee/0442).
Provenance and peer review not commissioned; externally peer reviewed.
data sharing statement additional data may be available by contacting the 
corresponding author.
Open Access this is an Open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY-nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. all rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1. Strand V, Rao SA, Shillington AC, et al. Prevalence of axial 
spondyloarthritis in United States rheumatology practices: 
assessment of spondyloarthritis international society criteria 
versus rheumatology expert clinical diagnosis. Arthritis Care Res 
2013;65:1299–306.
 2. Rudwaleit M, van der Heijde D, Landewé R, et al. The development 
of assessment of SpondyloArthritis international Society 
classification criteria for axial spondyloarthritis (part II): validation 
and final selection. Ann Rheum Dis 2009;68:777–83.
 3. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset 
and diagnosis delay in HLA-B27 negative vs. positive patients with 
ankylosing spondylitis. Rheumatol Int 2003;23:61–6.
 4. Ward MM. Health-related quality of life in ankylosing spondylitis: a 
survey of 175 patients. Arthritis Care Res 1999;12:247–55.
 5. Essers I, Ramiro S, Stolwijk C, et al. Characteristics associated with 
the presence and development of extra-articular manifestations in 
ankylosing spondylitis: 12-year results from OASIS. Rheumatology 
2015;54:633–40.
 6. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, et al. Prevalence 
of extra-articular manifestations in patients with ankylosing 
spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 
2015;74:65–73.
 7. Stolwijk C, Essers I, van Tubergen A, et al. The epidemiology of 
extra-articular manifestations in ankylosing spondylitis: a population-
based matched cohort study. Ann Rheum Dis 2015;74:1373–8.
 8. Hamilton L, Gilbert A, Skerrett J, et al. Services for people with 
ankylosing spondylitis in the UK--a survey of rheumatologists and 
patients. Rheumatology 2011;50:1991–8.
 9. Sykes MP, Doll H, Sengupta R, et al. Delay to diagnosis in axial 
spondyloarthritis: are we improving in the UK? Rheumatology 
2015;54:kev288–4.
 10. Seo MR, Baek HL, Yoon HH, et al. Delayed diagnosis is linked to 
worse outcomes and unfavourable treatment responses in patients 
with axial spondyloarthritis. Clin Rheumatol 2015;34:1397–405.
 11. Hermann KG, Baraliakos X, van der Heijde DM, et al. Descriptions 
of spinal MRI lesions and definition of a positive MRI of the spine 
in axial spondyloarthritis: a consensual approach by the ASAS/
OMERACT MRI study group. Ann Rheum Dis 2012;71:1278–88.
 12. Juanola X, Loza Santamaría E, Cordero-Coma M, et al. Description 
and prevalence of spondyloarthritis in patients with anterior uveitis: 
The SENTINEL interdisciplinary collaborative project. Ophthalmology 
2016;123:1632–6.
 13. Haroon M, O'Rourke M, Ramasamy P, et al. A novel evidence-based 
detection of undiagnosed spondyloarthritis in patients presenting 
with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). 
Ann Rheum Dis 2015;74:1990–5.
 14. Deodhar A. Editorial: Sacroiliac joint magnetic resonance imaging 
in the diagnosis of axial spondyloarthritis: “A tiny bit of white on 
two consecutive slices” may be objective, but not specific. Arthritis 
Rheumatol 2016;68:775–8.
 15. Deodhar A, Strand V, Kay J, et al. The term ‘non-radiographic 
axial spondyloarthritis’ is much more important to classify than 
to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 
2016;75:791–4.
 16. Sepriano A, Landewé R, van der Heijde D, et al. Predictive 
validity of the ASAS classification criteria for axial and peripheral 
spondyloarthritis after follow-up in the ASAS cohort: a final analysis. 
Ann Rheum Dis 2016;75:1034–42.
 17. van der Heijde D, Sieper J, Maksymowych WP, et al. Spinal 
inflammation in the absence of sacroiliac joint inflammation on 
magnetic resonance imaging in patients with active nonradiographic 
axial spondyloarthritis. Arthritis Rheumatol 2014;66:667–73.
 18. van Onna M, van Tubergen A, Jurik AG, et al. Natural course of bone 
marrow oedema on magnetic resonance imaging of the sacroiliac 
joints in patients with early inflammatory back pain: a 2-year follow-
up study. Scand J Rheumatol 2015;44:129–34.
 19. Baraliakos X, Sieper J, Chen S, et al. Non-radiographic axial 
spondyloarthritis patients without initial evidence of inflammation 
may develop objective inflammation over time. Rheumatology 
2017;56:1162–6.
 20. Fernández-Melón J, Muñoz-Fernández S, Hidalgo V, et al. 
Uveitis as the initial clinical manifestation in patients with 
spondyloarthropathies. J Rheumatol 2004;31:524–7.
copyright.
 o
n
 August 24, 2020 at University of East Anglia. Protected by
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000553 on 24 February 2018. Downloaded from
 
